BGC-20-1531

BGC-20-1531 (PGN 1531), a benzenesulfonamide derivative, is a selective EP4 antagonist. BGC-20-1531 binds to PGE2 enhancing the ATPase activity, which are coupled to Gs proteins and thus activate adenylate cyclase generating cAMP and activating PKA. BGC-20-1531 is promising for research of liver disorders[1][2].

Product Specifications

CAS Number

[1186532-61-5]

Product Name Alternative

PGN 1531

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

PKA; Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Stem Cell/Wnt; TGF-beta/Smad

Applications

Neuroscience-Neuromodulation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/bgc-20-1531.html

Smiles

O=C(C1=CC(COC2=CC=C(C3=NC=C(C=C3)OC)C=C2)=C(C)O1)N([Na])S(=O)(C4=C(C)C=CC=C4)=O

Molecular Formula

C26H23N2NaO6S

Molecular Weight

514.53

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

References & Citations

[1]Ammazzalorso A, et al. N-acylsulfonamides: Synthetic routes and biological potential in medicinal chemistry. Chem Biol Drug Des. 2017 Dec;90 (6) :1094-1105.|[2]Hodeify R, et al. PGE2 upregulates the Na+/K+ ATPase in HepG2 cells via EP4 receptors and intracellular calcium. PLoS One. 2021 Jan 14;16 (1) :e0245400.